Search Results for "Sjogren A Belimumab"

18:03 EDT 3rd May 2016 | BioPortfolio

Matching Channels


Matching News

Rheumatoid Factor Tied to Sjogren's Lymphoma (CME/CE)

(MedPage Today) -- Disease activity also contributed to blood cancer risk in Sjogren's syndrome


Class: Immunotherapy Generic Name: Belimumab Trade Name: Benlysta® For which conditions is this drug approved? Benlysta is approved to treat adults with active systemic lupus erythematosus (SLE or lu...

Biogen, OMRF partner in Sjogren's syndrome

Biogen Inc. and the Oklahoma Medical Research Foundation (OMRF) are teaming up to discover biomarkers that can be used to identify patients with Sjogren's syndrome who would be likely to respond to Bi...

Salivary Gland Histopathology in Primary Sjogren's Syndrome

Salivary gland biopsy is often used to diagnose primary Sjogren's syndrome. Can this biopsy also predict prognosis? Annals of the Rheumatic Diseases

Regulatory update – BLA filed for Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), for Benlysta (belim...

Regulatory update - Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), for Benlysta (belimumab) for reducing disease activi...

GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

GSK today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis - a condition that involves inf...

Stratifying primary Sjögren’s syndrome: killers in the balance?

The article by Seror et al. in Arthritis Research & Therapy reports data from the 15 French patients in the open-label BELISS (Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Synd...

Matching PubMed Articles

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.

Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...

Belimumab in systemic lupus erythematosus: a perspective review.

Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by...

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody, appeared effective in Sjögren's syndrome (SS) in the phase II open-label 52-week BELISS study. Herein, the follow-up after the en...

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...

Rituximab-refractory lupus nephritis successfully treated with belimumab.


Search Whole site using Google

Quick Search
Advertisement Advertisement